Browsing by Author "Monrroy Bravo, Hugo Alfonso"

Now showing 1 - 18 of 18
  • Thumbnail Image
    Item
    Aceptación y adherencia de una pauta de preparación de colon el mismo día del examen en población chilena
    (2015) Mansilla V., Rodrigo; Corsi S., Oscar; Glasinovic V., Esteban; Uslar N., Thomas; Monrroy Bravo, Hugo Alfonso; Candia Balboa, Roberto; González Donoso, Robinson; Álvarez Lobos, Manuel; Parra Blanco, Adolfo
  • Thumbnail Image
    Item
    Anxiety can significantly explain bolus perception in the context of hypotensive esophageal motility: Results of a large multicenter study in asymptomatic individuals
    (2017) Marín, I.; Serra J.; Cisternas, D.; Scheerens, C.; Omari, T.; Monrroy Bravo, Hugo Alfonso; Hani, A.; Leguizamo, A.; Bilder, C.; Ditaranto, A.; Ruiz de León, A.; Pérez de la Serna, J.; Valdovinos, M.; Coello, R.; Abrahao, L.; Remes Troche, J.; Meixueiro, A.; Zavala, M.
  • Thumbnail Image
    Item
    Claves prácticas para un trasplante de microbiota fecal por colonoscopía en infección por clostridium difficile recurrente. Experiencia en un centro universitario
    (2018) Cruz Urrutia, Ricardo Javier; Monrroy Bravo, Hugo Alfonso; Flandez, Jorge; Pérez, Carlos; Álvarez Lobos, Manuel; Hernández Rocha, Cristián Antonio
  • Thumbnail Image
    Item
    Detection of high biliary and fecal viral loads in patients with chronic hepatitis C virus infection
    (2017) Monrroy Bravo, Hugo Alfonso; Angulo, J.; Pino, Karla; Labbé, P.; Miquel P., Juan Francisco; López Lastra, Marcelo Andrés; Soza, Alejandro
  • No Thumbnail Available
    Item
    Direct antivirals for the treatment of chronic hepatitis C virus infection. Experience in 106 patients.
    (2017) Soza Ried, Alejandro; Benítez Gajardo, Carlos Esteban; Barrera Álvarez, Francisco Benjamín; Monrroy Bravo, Hugo Alfonso; Vargas Domínguez, José Ignacio; Arab Verdugo, Juan Pablo; Arrese Jiménez, Marco Antonio; Sarmiento, V.; Fuster, F.
    Background: The availability of direct-acting antivirals (DAA) for the treatment of chronic hepatitis C virus (HCV) infection is just starting to expand in Chile. Aim: To report the initial experience of patients treated with DAA and their evolution after treatment. Material and Methods: Prospective cohort study, from June 2013 to August 2016 of patients treated with DAA for HCV in three clinical centers. The presence of cirrhosis, clinical and laboratory features; adverse events (AE) and post-treatment changes in liver function were evaluated. Sustained viral response at 12 weeks post-treatment (SVR12) was determined. Results: One hundred six patients aged 58 +/- 13 years, 54% males, were included. HCV genotype 1b was present in 88% and 47% had cirrhosis. Treatment regimens were asunaprevir + daclatasvir (DCV) in 17% of patients, paritaprevir / ritonavir / ombitasvir + dasabuvir in 33%, sofosbuvir (SOF) + DCV in 19%, and SOF + ledipasvir in 30%. Twenty five percent of patients used generic drugs. SVR12 was 92.1%, with no differences between generic and brand-name drugs. Serious AE were recorded in 22% of patients, being more common in those with cirrhosis (34% vs 11.5%, p < 0.01). At 12 weeks post-treatment follow-up, there was a decrease in aminotransferase values (p < 0.01), improvement in Child-Pugh score (5.9 vs. 5.5, p = 0.03) and decreased presence of ascites (p = 0.02). Conclusions: In our setting, DAA for HCV was highly effective and safe in non-cirrhotic patients. Hepatic function and inflammation improved at 12 weeks of follow-up. AE were common in patients with cirrhosis, suggesting that these patients should be treated by experienced teams. Generic drugs had similar effectiveness compared to originals.
  • Thumbnail Image
    Item
    Effect of ezetimibe in HCV viral load after liver transplantation
    (2016) Monrroy Bravo, Hugo Alfonso; Angulo, J.; Pino, Karla; Labbé, P.; López Lastra, Marcelo Andrés; Soza, Alejandro
  • Thumbnail Image
    Item
    Esofagitis eosinofílica : Diagnóstico y manejo
    (2020) Ballart, M. J.; Monrroy Bravo, Hugo Alfonso; Iruretagoyena B., Mirentxu; Parada Daza, Alejandra; Torres Montes, Paula Javiera; Espino Espino, Alberto Antonio
  • No Thumbnail Available
    Item
    Fair reliability of eckardt scores in achalasia and non-achalasia patients: Psychometric properties of the eckardt spanish version in a multicentric study
    (2020) Cisternas, Daniel; Monrroy Bravo, Hugo Alfonso; Riquelme Pérez, Arnoldo; Padilla Pérez, Oslando; Fuentes López, Eduardo; Arturo Valle; Mejía Martínez, Ricardo Javier; Albis Hani; Andres F. Ardila-Hani; Ana Maria Leguizamo; Claudio Bilder; Andres Ditaranto; Jose Maria Remes-Troche; Antonio Ruiz de León; Julio Pérez de la Serna; Ingrid Marin; Jordi Serra
  • Thumbnail Image
    Item
    Hepatitis C virus may have an entero-hepatic cycle which could be blocked with ezetimibe
    (2017) Monrroy Bravo, Hugo Alfonso; López Lastra, Marcelo Andrés; Soza, Alejandro
  • No Thumbnail Available
    Item
    Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease—Authors' reply
    (2024) Idalsoaga Ferrer, Francisco Javier; Diaz Piga, Luis Antonio; Ayares Campos, Gustavo Ignacio; Cabrera, Daniel; Chahuan Abde, Javier Nicolas; Monrroy Bravo, Hugo Alfonso; Halawi, Houssam; Arrese Jiménez, Marco Antonio; Arab Verdugo, Juan Pablo
  • Thumbnail Image
    Item
    Nuevas terapias orales de acción directa para tratamiento de virus de hepatitis C (VHC)
    (2017) Vargas Domínguez, José Ignacio; Arab Verdugo, Juan Pablo; Monrroy Bravo, Hugo Alfonso; Labbé, Pilar; Sarmiento, Valeska; Fuster, Felipe; Barrera Martínez, Francisco Javier; Benitez, Carlos; Arrese Jiménez, Marco; Soza, Alejandro; Fuster, Francisco
  • Thumbnail Image
    Item
    Review article: Oesophageal disorders in chronic liver disease
    (WILEY, 2024) Idalsoaga Ferrer, Francisco Javier; Diaz Piga, Luis Antonio; Ayares Campos, Gustavo Ignacio; Cabrera, Daniel; Chahuan Abde, Javier Nicolas; Monrroy Bravo, Hugo Alfonso; Halawi, Houssam; Arrese Jimenez, Marco Antonio; Arab Verdugo, Juan Pablo
    Background: Oesophageal disorders and chronic liver disease are common worldwide and significantly impact quality of life. The intricate link between these conditions, including how oesophageal disorders like GERD, Barrett's oesophagus and oesophageal cancer affect and are affected by chronic liver disease, remains poorly understood. Aims: To review the relationship between oesophageal disorders and chronic liver disease, evaluating epidemiology, pathophysiology and therapeutic factors. Methods: We reviewed the literature on the relationship between oesophageal disorders and chronic liver disease, including cirrhosis, using the PubMed database Results: Oesophageal disorders such as gastroesophageal reflux disease, Barrett's oesophagus, oesophageal cancer, oesophageal motor disorders and oesophageal candidiasis are prevalent among individuals with cirrhosis, exacerbating the burden of liver disease. These diseases have a multifaceted symptomatology and pathogenic basis, posing a significant challenge in cirrhotic patients that necessitates careful diagnosis and management. Additionally, therapies frequently used for these diseases, such as proton pump inhibitors, require careful consideration in cirrhotic patients due to potential adverse effects and altered pharmacokinetics. Managing oesophageal disorders in cirrhotic patients requires a cautious approach due to possible interactions with medications and the risk of adverse effects. Furthermore, symptoms associated with these conditions are often exacerbated by common interventions in patients with cirrhosis, such as band ligation for oesophageal varices. Conclusions: Oesophageal disorders are common in cirrhosis and increase the disease burden. These conditions require careful management due to complex symptoms and treatment risks. Proton pump inhibitors and other therapies must be used cautiously, as cirrhosis interventions can worsen symptoms.
  • No Thumbnail Available
    Item
    The Brief Esophageal Dysphagia Questionnaire shows better discriminative capacity for clinical and manometric findings than the Eckardt score: results from a multicenter study
    (2022) Cisternas, Daniel; Taft, Tiffany; Carlson, Dustin A.; Glasinovic, Esteban; Monrroy Bravo, Hugo Alfonso; Rey, Paula; Hani, Albis; Ardila‐Hani, Andrés; Leguizamo, Ana María; Bilder, Claudio; Ditaranto, Andrés; Varela, Amanda; Agotegaray, Joaquin; Remes‐Troche, José María; Ruiz de León, Antonio; Pérez de la Serna, Julio; Marín, Ingrid; Serra, Jordi
    Abstract Introduction: Grading dysphagia is crucial for clinical management of patients. The Eckardt score (ES) is the most commonly used for this purpose. We aimed to compare the ES with the recently developed Brief Esophageal Dysphagia Questionnaire (BEDQ) in terms of their correlation and discriminative capacity for clinical and manometric findings and evaluate the effect of gastroesophageal reflux symptoms on both. Methods: Symptomatic patients referred for high-resolution manometry (HRM) were prospectively recruited from seven centers in Spain and Latin America. Clinical data and several scores (ES, BEDQ, GERDQ) were collected and contrasted to HRM findings. Standard statistical analysis was performed. Key results: 426 patients were recruited, 31.2% and 41.5% being referred exclusively for dysphagia and GERD symptoms, respectively. Both BEDQ and ES were independently associated with achalasia. Only BEDQ was independently associated with being referred for dysphagia and with relevant HRM findings. ROC curve analysis for achalasia diagnosis showed AUC of 0.809 for BEDQ and 0.765 for ES, with the main difference being higher BEDQ sensitivity (80.0% vs 70.8% for ES). GERDQ independently predicted ES but not BEDQ. In the absence of dysphagia (BEDQ = 0), GERD symptoms significantly determine ES. Conclusions and inferences: Our study suggests both the BEDQ and ES can complementarily describe symptomatic burden in achalasia. BEDQ has several advantages over the ES in the dysphagia evaluation, basically due to its higher sensitivity for manometric diagnosis and independence of GERD symptoms. ES should be used as an achalasia-specific metric, while BEDQ is a better symptom-generic evaluating tool.
  • Thumbnail Image
    Item
    The Chicago Classification 3.0 Results in More Normal Findings and Fewer Hypotensive Findings With No Difference in Other Diagnoses
    (2017) Monrroy Bravo, Hugo Alfonso; Cisternas, D.; Bilder, C.; Ditaranto, A.; Remes-Troche, J.; Meixueiro, A.; Zavala, M. A.; Serra, J.; Marín, I.; Ruiz De León, A.; Pérez de la Serna, J.; Hani, A.; Leguizamo, A.; Abrahao, L.; Coello, R.; Valdovinos, M. A.
  • No Thumbnail Available
    Item
    The Spanish version of the esophageal hypervigilance and anxiety score shows strong psychometric properties: results of a large prospective multicenter study in Spain and Latin America
    (2021) Cisternas, Daniel; Taft, Tiffany; Carlson, Dustin A.; Glasinovic, Esteban; Monrroy Bravo, Hugo Alfonso; Rey, Paula; Hani, Albis; Ardila‐Hani, Andrés; Leguizamo, Ana María; Bilder, Claudio; Ditaranto, Andrés; Varela, Amanda; Agotegaray, Joaquín; Remes‐Troche, José María; Ruiz de León, Antonio; Pérez de la Serna, Julio; Marín, Ingrid; Serra, Jordi
    Background Anxiety is a significant modulator of sensitivity along the GI tract. The recently described Esophageal Hypervigilance and Anxiety Score (EHAS) evaluates esophageal-specific anxiety. The aims of this study were as follows: 1. translate and validate an international Spanish version of EHAS. 2. Evaluate its psychometric properties in a large Hispano-American sample of symptomatic individuals. Methods A Spanish EHAS version was developed by a Delphi process and reverse translation. Patients referred for high-resolution manometry (HRM) were recruited prospectively from seven Spanish and Latin American centers. Several scores were used: EHAS, Hospital Anxiety and Depression Scale (HADS), Eckardt score (ES), Gastroesophageal Reflux Questionnaire (GERDQ), and the Brief Esophageal Dysphagia Questionnaire (BEDQ). Standardized psychometric analyses were performed. Key Results A total of 443 patients were recruited. Spanish EHAS showed excellent reliability (Cronbach´s alpha = 0.94). Factor analysis confirmed the presence of two factors, corresponding to the visceral anxiety and hypervigilance subscales. Sufficient convergent validity was shown by moderate significant correlations between EHAS and other symptomatic scores. Patients with high EHAS scores had significantly more dysphagia. There was no difference in EHAS scores when compared normal vs abnormal or major manometric diagnosis. Conclusions and Inferences A widely usable Spanish EHAS version has been validated. We confirm its excellent psychometric properties in our patients, confirming the appropriateness of its use in different populations. Our findings support the appropriateness of evaluating esophageal anxiety across the whole manometric diagnosis spectrum.
  • Thumbnail Image
    Item
    Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy Response
    (2018) Parra-Blanco, Adolfo; Monrroy Bravo, Hugo Alfonso; Ignacio Vargas, Jose; Candia, Roberto; González Donoso, Robinson
  • Thumbnail Image
    Item
    Use of N-acetylcysteine plus simethicone to improve mucosal visibility during upper GI endoscopy: a double-blind, randomized controlled trial
    (2018) Monrroy Bravo, Hugo Alfonso; Vargas Domínguez, José Ignacio; Glasinovic, Esteban; Candia, Roberto; Azua, Emilio; Galvez, Camila; Rojas, Camila; Cabrera, Natalia; Vidaurre, Josefa; Alvarez, Natalia; Gonzalez, Jessica; Espino Espino, Alberto Antonio; González Donoso, Robinson; Parra-Blanco
  • Thumbnail Image
    Item
    Validation and psychometric evaluation of the Spanish version of Brief Esophageal Dysphagia Questionnaire (BEDQ) : Results of a multicentric study
    (2020) Cisternas, D.; Taft, T.; Carlson, D. A.; Glasinovic, E.; Monrroy Bravo, Hugo Alfonso; Rey Gnecco, Paula; Hani, A.; Ardila Hani, A.; Leguizamo, A. M.; Bilder, C.; Ditaranto, A.; Varela, A.; Agotegaray, J.; Remes Troche, J. M.; Ruiz de León, A.; Pérez de la Serna, J.; Marin, I.; Serra, J.